<DOC>
	<DOC>NCT00890097</DOC>
	<brief_summary>The purpose of this study was to evaluate the safety and efficacy of AL-8309B Ophthalmic Solution versus Vehicle administered as a topical ocular drop for the treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).</brief_summary>
	<brief_title>Geographic Atrophy Treatment Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Willing to give written informed consent, make required study visits, and follow instructions. Able to administer eye drops or have a caretaker to administer the eye drops. Study eye: Atrophy secondary to agerelated macular degeneration, best corrected visual acuity (BCVA) of 35 letters (20/200 Snellen equivalent) or better, clear ocular media, and adequate pupillary dilation. Other protocoldefined inclusion criteria may apply. Pregnant, nursing, or not using adequate contraception. Ocular disease in the study eye, other than nonexudative AMD. History of cataract surgery in either eye within the past 3 months of screening. History or evidence of serious ocular trauma or intraocular surgery in either eye within the past 6 months of screening. Any medical condition that would make participation in the trial or adherence to the study schedule difficult or unlikely. Participation in an investigational drug or device study within 30 days of screening. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Geographic Atrophy</keyword>
	<keyword>GA</keyword>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>AMD</keyword>
</DOC>